Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
arGEN-X SE (GB:0QW0)
LSE:0QW0
arGEN X (0QW0) Share Price & Analysis
2 Followers
0QW0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€272.40 - €494.00
Previous Close€347.15
Volume1.05K
Average Volume (3M)26.30K
Market Cap
€20.50B
Enterprise Value€18.62B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)-72.7
Beta0.58
Next Earnings
Jul 25, 2024EPS Estimate
-€0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.77
Shares Outstanding59,431,079
10 Day Avg. Volume24,510
30 Day Avg. Volume26,299
Standard Deviation0.19
R-Squared0.09
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)12.99
Price to Sales (P/S)12.78
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue87.36
Enterprise Value/Gross Profit16.80
Enterprise Value/Ebitda-40.84
Forecast
1Y Price Target
€418.40Price Target Upside20.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
arGEN X News
Bulls Say, Bears Say
Bulls Say
Analyst's OutlookAnalyst raises the price target for ARGX, maintaining a Buy rating, which signals confidence in the company's valuation and future performance.
Drug DevelopmentPipeline progress remains on track, with a Phase 3 trial for Vyvgart in TED expected to start, which is a key positive development.
Product DifferentiationVyvgart's pre-filled syringe provides additional differentiation from potential competitors, such as IMVT's IMVT-1402.
Bears Say
Clinical Trial ResultsARGX shares have suffered following a Phase 3 trial miss for subcutaneous Vyvgart Hytrulo, shaking investor confidence in the drug's efficacy.
Financial ForecastThe reduction in the probability of success in BP to 25% and subsequent price target cut reflect growing skepticism around the drug's commercial potential.
Investment OutlookRecent clinical setbacks and a high placebo response rate in trials cast doubt on the reliability of results, potentially devaluing future revenue projections.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
13.04% Mutual Funds
6.66% Other Institutional Investors
80.30% Public Companies and
Individual Investors
0QW0 FAQ
What was arGEN-X SE’s price range in the past 12 months?
arGEN-X SE lowest share price was €272.40 and its highest was €494.00 in the past 12 months.
What is arGEN-X SE’s market cap?
Currently, no data Available
When is arGEN-X SE’s upcoming earnings report date?
arGEN-X SE’s upcoming earnings report date is Jul 25, 2024 which is in 68 days.
How were arGEN-X SE’s earnings last quarter?
arGEN-X SE released its earnings results on May 09, 2024. The company reported -€0.965 earnings per share for the quarter, missing the consensus estimate of -€0.718 by -€0.247.
Is arGEN-X SE overvalued?
According to Wall Street analysts arGEN-X SE’s price is currently Undervalued.
Does arGEN-X SE pay dividends?
arGEN-X SE does not currently pay dividends.
What is arGEN-X SE’s EPS estimate?
arGEN-X SE’s EPS estimate is -€0.82.
How many shares outstanding does arGEN-X SE have?
arGEN-X SE has 59,431,080 shares outstanding.
What happened to arGEN-X SE’s price movement after its last earnings report?
arGEN-X SE reported an EPS of -€0.965 in its last earnings report, missing expectations of -€0.718. Following the earnings report the stock price went down -8.299%.
Which hedge fund is a major shareholder of arGEN-X SE?
Currently, no hedge funds are holding shares in GB:0QW0
---
arGEN X Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.96%
12-Months-Change
Fundamentals
Return on Equity
-8.60%
Trailing 12-Months
Asset Growth
40.02%
Trailing 12-Months
Company Description
arGEN-X SE
argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.
---
0QW0 Stock 12 Month Forecast
Average Price Target
€418.40
▲(20.52% Upside)
Technical Analysis
Best Analysts Covering 0QW0
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+16.38%
reiterated a buy rating 5 days ago
Copying James Gordon's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +16.38% per trade.
---